Emile Voest is professor of Medical Oncology and serves as Medical Director on the executive board of the Netherlands Cancer Institute in Amsterdam.
He also serves as chair of the Center for Personalized Cancer Treatment (a national program involving academic cancer centers and teaching hospitals), as chair of the scientific council of the Pediatric Oncology Foundation (KiKa) and as medical director on the board of the HUB Foundation for Organoid Technology and Stemcell technology.
His translational research has focused on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers with emphasis on genetics and tumor organoids, and identification of new targets of treatment to overcome chemoresistance.
Dr Voest was registered as a medical doctor in 1985. He became board certified as an internist July 1993, and as a medical oncologist in January 1995. He completed his PhD program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells June 1993 (cum laude). In 1994 and 1995 he was a postdoctoral fellow of the Dutch Cancer Society. As a postdoctoral fellow he joined the laboratory of Dr. Judah Folkman, Children’s Hospital, Harvard Medical School, Boston and worked on endogenous inhibitors of angiogenesis. Thereafter he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. In November 1999 he became a full professor in Medical Oncology in Utrecht. He currently serves in a variety of scientific committees and advisory boards. He has several patents to his name in the field of angiogenesis and biomarkers. In 2011, he spend a 6 months sabbatical at UCSD on bioinformatics and systems biology. Until April 2014, he was chair of the scientific council of the Dutch Cancer Society (KWF).
He co-authored some 200 manuscripts that together have been cited almost 7,000 times.
Dr Voest serves as one of the Team Leaders in the Stand up to Cancer International Translational Research Grant “Prospective Use of DNA-guided Personalized Cancer Treatment”.